Results 21 to 30 of about 724,283 (165)

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

Clinical Drug Investigation, 2021
CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after ...
Matt Shirley (7340599)
openaire   +3 more sources

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study [PDF]

Annals of the Rheumatic Diseases, 2017
To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg)
Park, Won, Yoo, Dae Hyun, Miranda, Pedro, Brzosko, Marek, Wiland, Piotr, Gutierrez-Ureña, Sergio, Mikazane, Helena, Lee, Yeon Ah, Smiyan, Svitlana, Lim, Mie Jin, Kadinov, Vladimir, Abud-Mendoza, Carlos, Kim, Houng, Lee, Sang Joon, Bae, Yunju, Kim, Suyeon, Braun, Jürgen   +16 more
openaire   +5 more sources

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]

Clinical Case Reports, 2022
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased ...
Sooraj Vijayan, Kyungmin Hwangbo, Nick Barkham   +2 more
doaj   +2 more sources

The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis [PDF]

BMC Gastroenterology
Background Since 2015, an infliximab biosimilar, CT-P13, has been approved for commercial use in many countries, easing the economic burden borne by society and patients.
Xinyue Hu, Xiaowei Tang, Limin Li, Lian Luo, Xinsen He, Qin Yan, Xiaolin Zhong   +6 more
doaj   +2 more sources

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study [PDF]

Clinical and Translational Science, 2022
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and ...
Stefano Mazza, Nicole Piazza O. Sed, Francesco Simone Conforti, Alberto Fascì, Alessandro Rimondi, Beatrice Marinoni, Valentina Casini, Chiara Ricci, Francesca Munari, Lorena Pirola, Pietro Invernizzi, Carlo Girelli, Guido Lupinacci, Luca Pastorelli, Flaminia Cavallaro, Luca Ferraris, Alice Colucci, Arnaldo Amato, Gian Eugenio Tontini, Maurizio Vecchi, Gionata Fiorino, Flavio Caprioli   +21 more
doaj   +2 more sources

A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease [PDF]

Immunotherapy, 2017
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however ...
Farkas Klaudia, Molnár Tamás
openaire   +5 more sources

Outcomes of an Intravenous to Subcutaneous Infliximab (CT‐P13) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study [PDF]

ACR Open Rheumatology
Objectives To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA). Methods We conducted a prospective,
Luca Iorio, Federica Davanzo, Eleonora Fiorin, Marta Codirenzi, Roberta Prevedello, Andrea Doria, Roberto Padoan   +6 more
doaj   +2 more sources

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective [PDF]

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S. Alkhatib, Abdulaali R. Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H. Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A. Azzam, Mahmoud H. Mosli, Amal M. Badawoud, Majed S. Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +3 more sources

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice [PDF]

Intestinal Research, 2019
Background/Aims An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi   +8 more
doaj   +2 more sources

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report [PDF]

Clinical Case Reports, 2019
Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes.
Anne S. Strik, Geert R. D’Haens, Mark Löwenberg   +2 more
doaj   +2 more sources